Novartis Seeks EU Accelerated Review For CAR-T Therapy
Novartis, having now submitted its CAR-T therapy CTL019 to the European Medicines Agency for approval, should learn shortly whether the product will be assessed under the agency’s accelerated procedure.
You may also be interested in...
Products submitted for approval in the EU in recent weeks include Amgen/UCB’s potential new treatment for osteoporosis, romosozumab, an iv formulation of GSK’s flu treatment, zanamivir, and avacopan, a new immunosuppressant from ChemoCentryx that is getting support through the EMA’s PRIME scheme.
Lilly’s migraine prevention therapy, galcanezumab, is among the nine new products that companies have submitted to the European Medicines Agency for evaluation in recent weeks.
Phase III APOLLO results finally give the beleagured firm the first late-stage success for an RNAi thereapeutic and potentially a strong lead in the rare hereditary disease.